A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

April 3, 2026

Study Completion Date

July 28, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

BAT8008 injection

BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

DRUG

BAT1308 injection

One vial of 4 mL of concentrate contains 100 mg of BAT1308

Trial Locations (1)

310005

Song ZhengBo, Hangzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY